Log in to search using one of your social media accounts:

 

FDA Drug Safety Communication: Reminder to healthcare providers and patients to enroll in the Avandia-Rosiglitazone Medicines Access Program
[11-04-2011] The U.S. Food and Drug Administration (FDA) is reminding healthcare providers and patients about the need to enroll in the Avandia-Rosiglitazone Medicines Access Program by November 17, 2011 in order to continue prescribing and receiving rosiglitazone-containing medicines (Avandia, Avandamet, and Avandaryl). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - August 1, 2017 Category: Drugs & Pharmacology Source Type: news

FDA Drug Safety Communication: FDA requires removal of some prescribing and dispensing restrictions for rosiglitazone-containing diabetes medicines
The U.S. Food and Drug Administration (FDA) has determined that recent data for rosiglitazone-containing drugs, such as Avandia, Avandamet, Avandaryl, and generics, do not show an increased risk of heart attack compared to the standard type 2 diabetes medicines metformin and sulfonylurea. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - August 1, 2017 Category: Drugs & Pharmacology Source Type: news

rosiglitazone, Avandia
Title: rosiglitazone, AvandiaCategory: MedicationsCreated: 11/28/1999 12:00:00 AMLast Editorial Review: 5/15/2017 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - May 15, 2017 Category: Endocrinology Source Type: news

Taking Aim At The Opioid Industry
Late last year, the Associated Press combined reporting with the Center for Public Integrity to roll out a multi-part series on the $880 million spent on lobbying and political contributions by the opioid industry in a decade long effort to stymie efforts to control these powerful drugs. Reporters reviewed of hundreds of documents brought to light in a recent court case and interviewed over 200 officials, experts, and advocates to understand how the opioid epidemic unfolded. The series had its genesis when the AP’s Matthew Perrone tripped across a group called the Pain Care Forum. Led by the top lobbyist for Purdue P...
Source: Healthy Living - The Huffington Post - March 7, 2017 Category: Consumer Health News Source Type: news

Avandia (Rosiglitazone Maleate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 3, 2017 Category: Drugs & Pharmacology Source Type: news

Avandaryl (Rosiglitazone Maleate and Glimepiride) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 19, 2016 Category: Drugs & Pharmacology Source Type: news

Avandamet (Rosiglitazone Maleate and Metformin HCl) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 18, 2016 Category: Drugs & Pharmacology Source Type: news

Expensive New Diabetes Drugs Add Nothing But Cost And Complications
This is the fourth in an ongoing series of blogs exposing the rampant misuse of the medications so aggressively promoted by greedy drug companies. I am very lucky in having the perfect partner in this truth-vs-power effort to contradict Pharma propaganda with evidence based fact. Dick Bijl is President of the International Society of Drug Bulletins (ISDB), an impressive association of 53 national drug bulletins from all around the world, each of which publishes the best available data on the pluses and minuses of different medications. Drug bulletins help patients and doctors see through the misleading misinformation ge...
Source: Science - The Huffington Post - November 17, 2016 Category: Science Source Type: news

Avandamet (rosiglitazone/metformin)
Title: Avandamet (rosiglitazone/metformin)Category: MedicationsCreated: 3/2/2005 12:00:00 AMLast Editorial Review: 9/21/2016 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - September 21, 2016 Category: Endocrinology Source Type: news

3 Drugs with the Most Severe Side Effects
Image Source Drugs have been known to have some sort of side effects on patients. Most of them are not often discussed in the health tabloids. While other drugs have side effects that are very nominal when compared to the benefits the patient derives from their usage, others have side effects that can impact the lives of their users forever. The most common side effects people experience from drug usage are gastrointestinal related issues which include constipation, nausea, and vomiting. Some other drugs can leave you feeling tired and dizzy for a short period of time. Combining these drugs with simple aspirin will usuall...
Source: Healthy Living - The Huffington Post - August 19, 2016 Category: Consumer Health News Source Type: news

La FDA elimina la Estrategia de Evaluación y Mitigación de Riesgos (REMS) para medicamentos para la diabetes que contienen rosiglitazona
[12-16-2015] La Administración de Alimentos y Medicamentos de Estados Unidos (FDA por sus siglas en inglés) está eliminando la Estrategia de Evaluación y Mitigación de Riesgos (REMS por sus siglas en inglés) para los medicamentos para la diabetes de tipo 2 que contienen rosiglitazona, que están aprobados como Avandia, Avandamet, Avandaryl y los genéricos. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 22, 2016 Category: Drugs & Pharmacology Source Type: news

La FDA elimina la Estrategia de Evaluaci ón y Mitigación de Riesgos (REMS) para medicamentos para la diabetes que contienen rosiglitazona
[12-16-2015] La Administraci ón de Alimentos y Medicamentos de Estados Unidos (FDA por sus siglas en inglés) está eliminando la Estrategia de Evaluación y Mitigación de Riesgos (REMS por sus siglas en inglés) para los medicamentos para la diabetes de tipo 2 que contienen rosiglitazona, que están aprobados como Avandia, A vandamet, Avandaryl y los genéricos. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 22, 2016 Category: Drugs & Pharmacology Source Type: news

La FDA elimina la Estrategia de Evaluaci ó n y Mitigaci ó n de Riesgos (REMS) para medicamentos para la diabetes que contienen rosiglitazona
[12-16-2015] La Administraci ó n de Alimentos y Medicamentos de Estados Unidos (FDA por sus siglas en ingl é s) est á eliminando la Estrategia de Evaluaci ó n y Mitigaci ó n de Riesgos (REMS por sus siglas en ingl é s) para los medicamentos para la diabetes de tipo 2 que contienen rosiglitazona, que est á n aprobados como Avandia, Avandamet, Avandaryl y los gen é ricos. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 22, 2016 Category: Drugs & Pharmacology Source Type: news

FDA Follies, Part 2
Part 1 of this series appeared just over a year ago (in a different publication), and detailed a few of the agency's recent missteps. Prominently mentioned was the sad case of certain diabetes meds, including Actos, once touted as a safer alternative to Avandia. Avandia was taken off the market in 2011, but reappeared subject to severe limitations of use. These limitations were later removed—although current usage of the drug is small. Oddly, Actos (FDA approved in July, 1999) was showing some problems (bladder cancer) as early as 2005, even though this information was not widely disseminated at the time. Some migh...
Source: Healthy Living - The Huffington Post - May 17, 2016 Category: Consumer Health News Source Type: news

FDA Drug Safety Communication: Avandia (rosiglitazone) labels now contain updated information about cardiovascular risks and use in certain patients
[2-03-2011] The U.S. Food and Drug Administration (FDA) is notifying the public that information on the cardiovascular risks (including heart attack) of the diabetes drug rosiglitazone has been added to the physician labeling and patient Medication Guide. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - April 8, 2016 Category: Drugs & Pharmacology Source Type: news

FDA Drug Safety Communication: Reminder to healthcare providers and patients to enroll in the Avandia-Rosiglitazone Medicines Access Program
[11-04-2011] The U.S. Food and Drug Administration (FDA) is reminding healthcare providers and patients about the need to enroll in the Avandia-Rosiglitazone Medicines Access Program by November 17, 2011 in order to continue prescribing and receiving rosiglitazone-containing medicines (Avandia, Avandamet, and Avandaryl). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - April 1, 2016 Category: Drugs & Pharmacology Source Type: news

Pioglitazone, Not Rosiglitazone, Again Tied to Bladder CancerPioglitazone, Not Rosiglitazone, Again Tied to Bladder Cancer
"Substantial and fairly consistent" evidence points to pioglitazone as associated with increased risk of bladder cancer, and this study strengthens and "confirms" that evidence, an expert says. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - April 1, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Diabetes drug linked to increased bladder cancer risk
Conclusion It seems likely from this research that pioglitazone is linked to an increased risk of bladder cancer, although the overall chances of getting bladder cancer remain very low. While this type of research cannot prove that pioglitazone is the cause of the increased risk of bladder cancer, it is not easy to find a convincing alternative explanation for these results. Previous research has already shown unexpectedly higher levels of bladder cancer among people taking pioglitazone, although other studies had found no such link. However, the size and the care with which this new study was carried out makes it convinc...
Source: NHS News Feed - March 31, 2016 Category: Consumer Health News Tags: Cancer Diabetes Medication Source Type: news

FDA Statement on Avandia TIDE Trial
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 11, 2016 Category: Drugs & Pharmacology Source Type: news

Comunicado de la FDA sobre la seguridad de los medicamentos: FDA requiere que se eliminen ciertas restricciones al recetar y dispensar medicamentos para la diabetes que contienen rosiglitazona
El 25 de noviembre, 2013, La Administración de Alimentos y Medicamentos de Estados Unidos (FDA por sus siglas en inglés) ha determinado que datos recientes sobre medicamentos que contienen rosiglitazona, como Avandia, Avandamet, Avandaryl y versiones genéricas, no indican un riesgo mayor de ataque al corazón en comparación con los medicamentos estándar metformina y sulfonilurea para la diabetes de tipo 2. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 1, 2016 Category: Drugs & Pharmacology Source Type: news

FDA Drug Safety Communication: FDA requires removal of some prescribing and dispensing restrictions for rosiglitazone-containing diabetes medicines
The U.S. Food and Drug Administration (FDA) has determined that recent data for rosiglitazone-containing drugs, such as Avandia, Avandamet, Avandaryl, and generics, do not show an increased risk of heart attack compared to the standard type 2 diabetes medicines metformin and sulfonylurea. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 19, 2016 Category: Drugs & Pharmacology Source Type: news

REMS No Longer Necessary for Rosiglitazone-Containing Diabetes Drugs (FREE)
By Kristin J. Kelley Edited by Susan Sadoughi, MD, and Richard Saitz, MD, MPH, FACP, FASAM The Risk Evaluation and Mitigation Strategy (REMS) for rosiglitazone-containing … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - December 17, 2015 Category: Primary Care Source Type: news

FDA Lifts Final Regulatory Restrictions on RosiglitazoneFDA Lifts Final Regulatory Restrictions on Rosiglitazone
The FDA pulls the plug on its prior risk evaluation and mitigation strategy for rosiglitazone-containing type 2 diabetes medicines. News Alerts (Source: theHeart.org)
Source: theHeart.org - December 16, 2015 Category: Cardiology Tags: Diabetes & Endocrinology News Alert Source Type: news

FDA Lifts Restriction On Rosiglitazone
(MedPage Today) -- Agency sees no need for restrictions after easing them 2 years ago (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - December 16, 2015 Category: Cardiology Source Type: news

Rosiglitazone-containing Diabetes Medicines: Drug Safety Communication - FDA Eliminates the Risk Evaluation and Mitigation Strategy (REMS)
The REMS is no longer necessary to ensure that the benefits of rosiglitazone medicines outweigh their risks. (Source: FDA MedWatch)
Source: FDA MedWatch - December 16, 2015 Category: American Health Source Type: news

A New Approach to Revolutionize Clinical Trials
It may be the biggest thing in medicine in a long time. It's not a new drug, or therapy or discovery. Instead it's a new way of doing clinical trials which could have a dramatic effect, particularly on those diseases that get less attention. Initially it is aimed at the deadliest brain cancer, glioblastoma multiforme, known as GBM. From diagnosis, it can kill in about six months. Traditionally clinical trials test one drug or a therapy on a lot of patients, sometimes thousands, against a control group that is treated with a placebo, or not treated at all. Trials drag on for years. The aim in clinical trials, which are cert...
Source: Science - The Huffington Post - December 8, 2015 Category: Science Source Type: news

New adipogenic cocktail that produces functional adipocytes from mesechymal stromal cells
Multipotent mesechymal stromal cells (MSCs) have been recognized as a source of adipocytes both in vivo and in vitro. It is reported that, simultaneous activation of canonical signaling pathways by dexamethasone through the glucocorticoid receptor and CCAAT-enchancer-binding proteins (C/EBPs) and rosiglitazone through peroxisome proliferator-activated receptor gamma (PPAR-gamma), is sufficient for inducing adipogenic differentiation from MSCs, producing functional adipocytes. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - October 8, 2015 Category: Science Source Type: news

Avandamet (rosiglitazone/metformin)
Title: Avandamet (rosiglitazone/metformin)Category: MedicationsCreated: 3/2/2005 12:00:00 AMLast Editorial Review: 8/20/2015 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - August 20, 2015 Category: Endocrinology Source Type: news

Ubc9 Enzyme Eyed as Potential Target for Diabetes Therapy
(MedPage Today) -- Inhibiting Ubc9 may boost potency of diabetic meds like rosiglitazone (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - August 9, 2015 Category: Cardiology Source Type: news

Common Diabetes Meds Tied to Lower Risk for Parkinson's
Study can't prove cause and effect, but saw dip in odds for people taking drugs such as Actos and Avandia (Source: WebMD Health)
Source: WebMD Health - July 22, 2015 Category: Consumer Health News Source Type: news

Common Diabetes Meds Tied to Lower Risk for Parkinson's
Study can't prove cause and effect, but saw dip in odds for people taking drugs such as Actos and Avandia Source: HealthDay Related MedlinePlus Pages: Diabetes Medicines, Parkinson's Disease (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - July 21, 2015 Category: Consumer Health News Source Type: news

Diabetes drugs not linked to bladder cancer
Study counters previous reports linking bladder cancer to use of pioglitazoneRelated items from OnMedicaNew study underlines rosiglitazone cardiovascular riskRegulators suspend Avandia over safety concernsAdding insulin to metformin linked to higher mortalityExperts query risks of pioglitazoneUse pioglitazone only in selected patients, says EMA guidance (Source: OnMedica Latest News)
Source: OnMedica Latest News - December 4, 2014 Category: UK Health Source Type: news

Hormone therapy treatment helps treat type 2 diabetes well
Drug combination more effective than current diabetes treatmentsRelated items from OnMedicaRegulators suspend Avandia over safety concernsUse pioglitazone only in selected patients, says EMA guidanceSugar not saturated fat is the major issue for CVDAdding insulin to metformin linked to higher mortalityExperts query risks of pioglitazone (Source: OnMedica Latest News)
Source: OnMedica Latest News - September 12, 2014 Category: UK Health Source Type: news

05.20.14 -- FDA Lifts Restrictions On GSK's Avandia; Three Questions To Consider For DQSA Readiness
05/20/14Pharmaceutical Online Newsletter (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - May 19, 2014 Category: Pharmaceuticals Source Type: news

Statins aren't a wonder drug | Malcolm Kendrick
The claims made for statins are overblown. They are not a cure for most of the major diseases afflicting western civilisationStatins are the most widely prescribed drugs in medical history. They appear to have effortlessly conquered heart disease. If guidance proposed by Nice – the National Institute for Health and Care Excellence – is followed, 15 million people in the UK, most with no history of heart disease, could soon be taking them.A recent study by researchers at Imperial College London made the claim that "statins have virtually no side effects, with users experiencing fewer adverse symptoms than i...
Source: Guardian Unlimited Science - March 23, 2014 Category: Science Authors: Malcolm Kendrick Tags: Comment The Guardian World news Health Health policy Society Drugs UK news Statins Comment is free Source Type: news

Statins aren't a wonder drug | Malcolm Kendrick
This article was corrected on 24 March 2014. It originally said in the eighth paragraph: "Flecainide suppressed dangerous heart arrhythmias, but was pulled from the market for killing thousands of people." This has been amended, as the drug that was pulled from the market was encainide, not flecainide.StatinsDrugsHealthHealth policyMalcolm Kendricktheguardian.com © 2014 Guardian News and Media Limited or its affiliated companies. All rights reserved. | Use of this content is subject to our Terms & Conditions | More Feeds (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - March 23, 2014 Category: Science Authors: Malcolm Kendrick Tags: Statins Drugs Health Health policy Society UK news World news The Guardian Comment Comment is free Source Type: news

Cardiovascular safety of antidiabetes drugs in doubt
Clinical trials need to assess heart failure riskRelated items from OnMedicaCaution urged over intensive glucose controlNew study underlines rosiglitazone cardiovascular riskExperts query risks of pioglitazoneDrugs regulators “put profits before patients”Daily aspirin use linked to major bleeding (Source: OnMedica Latest News)
Source: OnMedica Latest News - March 13, 2014 Category: UK Health Source Type: news

Older diabetes patients at higher risk, research shows
Age and diabetes duration raise risk of hypos and CV complicationsRelated items from OnMedicaMetformin reduces cardiovascular riskNew study underlines rosiglitazone cardiovascular riskInsulin pump with glucose sensor cuts risk of hyposLess than 50% of diabetics achieve blood pressure targetsPatients with diabetes make up over quarter of admissions for heart failure (Source: OnMedica Latest News)
Source: OnMedica Latest News - December 10, 2013 Category: UK Health Source Type: news

FDA lifts rosiglitazone prescribing restrictions
Read the full story on MD Consult: FDA lifts rosiglitazone prescribing restrictions (Source: MD Consult: News: Top Stories)
Source: MD Consult: News: Top Stories - December 4, 2013 Category: Journals (General) Source Type: news

FDA lifts constraints on Glaxo diabetes drug Avandia (Reuters, 25 November 2013)
The US Food and Drug Administration (FDA) has announced it will lift certain restrictions placed on the diabetes drug Avandia (rosiglitazone). Full article FDA announcement (Source: Society for Endocrinology)
Source: Society for Endocrinology - November 27, 2013 Category: Endocrinology Source Type: news

Avandia Decision a Moot Point for Prescribers?
(MedPage Today) -- It's unlikely that the FDA's decision to loosen some of the restrictions on the type 2 diabetes drug rosiglitazone (Avandia) will have any impact on prescribing in the U.S., according to several experts contacted by MedPage Today. (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - November 26, 2013 Category: American Health Source Type: news

Few See Renewed Role for Rosiglitazone in DiabetesFew See Renewed Role for Rosiglitazone in Diabetes
The question on everyone's lips now is what will happen to rosiglitazone. Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 26, 2013 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news

FDA to Lift Restrictions on Diabetes Drug Avandia
Title: FDA to Lift Restrictions on Diabetes Drug AvandiaCategory: Health NewsCreated: 11/25/2013 5:36:00 PMLast Editorial Review: 11/26/2013 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - November 26, 2013 Category: Endocrinology Source Type: news

With No Increase in MI Risk Found, Some Avandia Restrictions Lifted (FREE)
By Amy Orciari Herman Certain restrictions on the diabetes drug rosiglitazone (Avandia) are being removed because a new analysis from the RECORD trial has found no increase in myocardial infarction risk — a risk first suggested by a 2007 meta-analysis.In 2010, the FDA ruled … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - November 26, 2013 Category: Primary Care Source Type: news

F.D.A. Lifts Some Restrictions on Avandia
Doctors said the move was unlikely to breathe new life into the diabetes drug, which has been largely discredited in the United States.     (Source: NYT)
Source: NYT - November 26, 2013 Category: American Health Authors: By SABRINA TAVERNISE Tags: Drugs (Pharmaceuticals) Avandia (Drug) Food and Drug Administration Diabetes GlaxoSmithKline PLC GSK NYSE Source Type: news

FDA Removes Marketing Limits on Diabetes Drug Avandia
The FDA, in a U-turn from its position three years ago, removed the restrictions it imposed on the sale of GlaxoSmithKline's diabetes drug Avandia. (Source: WSJ.com: Health)
Source: WSJ.com: Health - November 26, 2013 Category: Pharmaceuticals Tags: PAID Source Type: news

FDA Removes Restrictions On Avandia
In a remarkable climax to a long-running drama, the FDA today lifted major restrictions on rosiglitazone (Avandia, GlaxoSmithKline). The drug has been the subject of  intense criticism and controversy since the 2007 publication of the famous Nissen meta-analsysis that first raised the possibility that the blockbuster diabetes drug might increase the risk of heart attack and cardiovascular death. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - November 25, 2013 Category: Pharmaceuticals Authors: Larry Husten Source Type: news

FDA Lifts Avandia Prescribing RestrictionsFDA Lifts Avandia Prescribing Restrictions
After a 2-day advisory committee meeting last June, the FDA has decided that current data do not suggest that the drug poses an increased cardiovascular risk. News Alerts (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 25, 2013 Category: Cardiology Tags: Diabetes & Endocrinology News Alert Source Type: news

GSK Responds to FDA Decision on Avandia (rosiglitazone)
GSK plc [LSE/NYSE: GSK] announced today that the U.S. Food and Drug Administration (FDA) has eased restrictions on patient access to Avandia (rosiglitazone), following an FDA Advisory Committee review in June 2013. (Source: GSK news)
Source: GSK news - November 25, 2013 Category: Pharmaceuticals Source Type: news